05.12.2012 Views

pravilnik o listi lekova koji se propisuju i izdaju na teret sredstava ...

pravilnik o listi lekova koji se propisuju i izdaju na teret sredstava ...

pravilnik o listi lekova koji se propisuju i izdaju na teret sredstava ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

1031<br />

043<br />

prema Pravilniku o standardima za primenu citostatika.<br />

L01X<br />

X11 estramustin<br />

L01X<br />

X11<br />

estramus<br />

tin<br />

ESTRAC<br />

YT<br />

kapsula<br />

100<br />

po<br />

140<br />

mg<br />

Pfizer<br />

Italia<br />

S.R.L.<br />

Italija 10.37<br />

5,80<br />

- - 50,00<br />

Karcinom prostate, hormon refraktorni, u slučaju kontraindikacija za<br />

INDIKACIJ<br />

primenu docetak<strong>se</strong>la, PS 0, 1 ili 2, prema Pravilniku o standardima za<br />

E<br />

primenu citostatika<br />

L02 ENDOKRINOLOŠKA TERAPIJA<br />

L02A Hormoni i srodni lekovi<br />

L02A<br />

Progestogeni<br />

B<br />

L02A<br />

B01 megestrol<br />

3048<br />

912<br />

1048<br />

911<br />

1048<br />

913<br />

3048<br />

814<br />

3048<br />

951<br />

L02A<br />

B01<br />

L02A<br />

B01<br />

L02A<br />

B01<br />

L02A<br />

B01<br />

L02A<br />

B01<br />

INDIKACIJ<br />

E<br />

megestro<br />

l<br />

megestro<br />

l<br />

megestro<br />

l<br />

megestro<br />

l<br />

megestro<br />

l<br />

MEGACE<br />

oral<strong>na</strong><br />

suspenzij<br />

a<br />

MEGACE tableta<br />

MEGACE tableta<br />

O'<br />

TENTIKA<br />

MEGOXI<br />

oral<strong>na</strong><br />

suspenzij<br />

a<br />

oral<strong>na</strong><br />

suspenzij<br />

a<br />

boca<br />

plastič<br />

<strong>na</strong>, 1<br />

po<br />

240<br />

ml (40<br />

mg/ml<br />

)<br />

bočic<br />

a, 100<br />

po<br />

160<br />

mg<br />

bočic<br />

a, 30<br />

po<br />

160<br />

mg<br />

boca<br />

plastič<br />

<strong>na</strong>, 1<br />

po<br />

240ml<br />

(40<br />

mg/ml<br />

)<br />

boca<br />

plastič<br />

<strong>na</strong>, 1<br />

po240<br />

ml (40<br />

mg/ml<br />

)<br />

Bristol<br />

Myers-<br />

Squibb<br />

Bristol<br />

Myers-<br />

Squibb<br />

Bristol<br />

Myers-<br />

Squibb<br />

Vipharm<br />

S.A.<br />

PharmaS<br />

wiss<br />

d.o.o.<br />

Francu<br />

ska<br />

Francu<br />

ska<br />

Francu<br />

ska<br />

7.929,<br />

90<br />

12.93<br />

1,20<br />

3.879,<br />

40<br />

7.929,<br />

Poljska<br />

90<br />

Republ<br />

ika<br />

Srbija<br />

7.929,<br />

90<br />

16<br />

0<br />

m<br />

g<br />

16<br />

0<br />

m<br />

g<br />

16<br />

0<br />

m<br />

g<br />

16<br />

0<br />

m<br />

g<br />

16<br />

0<br />

m<br />

g<br />

132,<br />

17 50,00<br />

129,<br />

31 50,00<br />

129,<br />

31 50,00<br />

132,<br />

17 50,00<br />

132,<br />

17 50,00<br />

Terapija nevoljnog z<strong>na</strong>čajnog gubitka telesne težine kod pacije<strong>na</strong>ta sa<br />

nehematološkim malignitetima (solidnim tumorima) . Pacijenti moraju imati

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!